慢性丙型肝炎患者心血管疾病研究进展

doi:10.3969/j.issn.1672-5069.2016.06.037

Abstract

Guo Zhaoxia，Wang Yuzhen，Su Shaohui.. Prevalence of cardiovascular diseases in patients with chronic hepatitis C[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 757-761.

[1] Irshad M，Mankotia DS，Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol，2013，19:7896-7909.
[2] Ko HM， Hernandez-Prera JC，Zhu H，et al. Morphologic features of extrahepatic manifestations of hepatitis C virus infection. Clin Dev Immunol，2012，2012:74.
[3] Zampino R，Marrone A，Restivo L，et al. Chronic HCV infection and inflmmation:clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol，2013，5:528-540.
[4] Alyan O， Kacmaz F，Ozdemir O，et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defied by modifid Reardon severity score system. Circ J，2008，72:1960-1965.
[5] Leandro G，Mangia A，Hui J，et al. HCV Meta-analysis （on） individual patients’data study group. Relationship between steatosis，inflmmation，and firosis in chronic hepatitisC:a meta-analysis of individual patient data. Gastroenterology，2006，130:1636-1642.
[6] Butt AA，Xiaoqiang W，Budoff M，et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis，2009，49:225-232.
[7] Sandler NG，Koh C，Roque A，et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology，2011，141:1220-1230.
[8] Coppola N，Zampino R，Bellini G，et al. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflmmation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol，2014，12:334-340.
[9] Sansonno D，Tucci FA，Ghebrehiwet B，et al. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol，2009，183:6013-6020.
[10] Terrier B，Karras A，Cluzel P，et al. Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol，2013，111:265-272.
[11] Younossi ZM，Stepanova M，Nader F，et al. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther，2013，37:647-652.
[12] Jin O，Sole MJ，Butany JW，et al. Detection of enterovirus RNA in myocardial biopsies from patients with myocarditis and cardiomyopathy using gene amplification by polymerase chain reaction. Circulation，1990，82:8-16.
[13] Akhtar N，Ni J，Stromberg D，et al. Tracheal aspirate as a substrate for polymerase chain reaction detection of viral genome in childhood pneumonia and myocarditis. Circulation，1999，99:2011-2018.
[14] Okabe M，Fukuda K，Arakawa K，et al. Chronic variant of myocarditis associated with hepatitis c virus infection. Circulation，1997，96:22-24.
[15] Sherker AH，Twu JS，Reyes GR，et al. Presence of viral replicative intermediates in the liver and serum of patients infected with hepatitis C virus. J Med Virol，1993，39:91-96.
[16] Yoshiyama M，Omura T，Takeuchi K，et al. Angiotensin blockade inhibits increased JNKs，AP-1 and NF-kappa B DNA- binding activities in myocardial infarcted rats. J Mol Cell Cardiol，2001，33:799-810.
[17] Omura T，Yoshiyama M，Yoshida K，et al. Dominant negative mutant of c-Jun inhibits cardiomyocyte hypertrophy induced by endothelin 1 and phenylephrine. Hypertension，2002，39:81-86.
[18] Omura T，Yoshiyama M， Hayashi T，et al. Core protein of hepatitis C virus induces cardiomyopathy. Circ Res，2005，96:148-150.
[19] Arbustini E，Diegoli M，Fasani R，et al. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am J Pathol，1998，153:1501-1510.
[20] Moriya K，Fujie H，Shintani Y，et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med，1998，4:1065-1067.
[21] Vassalle C，Masini S，Bianchi F，et al. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart，2004，90:565-566.
[22] Shah PK. Link between infection and atherosclerosis:who are the culprits:viruses，bacteria，both，or neither Circulation，2001，103:5-6.
[23] Oliveira CP，Kappel CR，Siqueira ER，et al. Effects of hepatitis C virus on cardiovascular risk in infected patients:a comparative study. Int J Cardiol，2013，164:221-226.
[24] Yang SS，Tsai G，Wu CH，et al. Circulating soluble intercellular adhesion molecule-1 in type C viral hepatitis. Hepatogastroenterology，1996，43:575-581.
[25] Lamprecht P，Moosig F，Gause A，et al. Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis，2001，60（4）:385-390.
[26] Matsumori A，Yutani C，Ikeda Y，et al. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest，2000，80（7）:1137-1142.
[27] Matsumori A. Role of hepatitis C virus in cardiomyopathies. Ernst Schering Res Found Workshop，2006，55:99-120.
[28] Millasseau SC， Stewart AD，Patel SJ，et al. Evaluation of carotid-femoral pulse wave velocity:inflence of timing algorithm and heart rate. Hypertension，2005，45:222-226.
[29] Tomiyama H，Arai T，Hirose K，et al. Hepatitis C virus seropositivity，but not hepatitis B virus carrier or seropositivity，associated with increased pulse wave velocity. Atherosclerosis，2003，166:401-403.
[30] Mostafa A，Mohamed MK，Saeed M，et al. Hepatitis C infection and clearance:impact on atherosclerosis and cardiometabolic risk factors. Gut，2010，59:1135-1140.
[31] Freiberg MS，Chang CC，Skanderson M，et al. Veterans Aging Cohort Study.The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes，2011，4:425-432.
[32] Matsumori A，Shimada T，Chapman NM，et al. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail，2006，12:293-298.
[33] Matsumori A. Hepatitis C virus and cardiomyopathy. Intern Med，2001，40:78-79.
[34] Dalekos GN，Achenbach K，Christodoulou D，et al. Idiopathic dilated cardiomyopathy:lack of association with hepatitis C virus infection. Heart，1998，80:270-275.
[35] Reis FJ，Viana M，Oliveira M，et al. Prevalence of hepatitis C and B virus infection in patients with idiopathic dilated cardiomyopathy in Brazil:a pilot study. Braz J Infect Dis，2007，11:318-321.
[36] Matsumori A，Matoba Y，Nishio R，et al. Detection of hepatitis c virus RNA from the heart of patients with hypertrophic cardiomyopathy. Biochem Biophys Res Commun，1996，222：678-682.
[37] Mason JW，O’Connell JB，Herskowitz A，et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med，1995，333:269-275.
[38] Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res，2005，96:144-147.
[39] Kcomt W，Nahavandi AA，Myaing M. et al. Hepatitis C and the heart:to beat or not to beat. Int J Cardiol，2004，96:147-149.
[40] Durante-Mangoni E，Ragone E，Pinto D，et al. Outcome of treatment with pegylated interferon and ribavirin in heart transplant recipients with chronic hepatitis C. Transplant Proc，2011，43:299-303.
[41] Marelli D，Bresson J，Laks H，et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant，2002，2:443-447.
[42] Ong JP，Barnes DS，Younossi ZM，et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology，1999，30:1293-1298.
[43] Gasink LB，Blumberg EA，Localio AR，et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA，2006，296:1843-1850.
[44] Lin MH，Chou NK，Chi NH，et al. The outcome of heart transplantation in hepatitis C-positive recipients. Transplant Proc，2012，44:890-893.
[45] Lake KD，Smith CI，Milfred-La Forest SK，et al. Outcomes of hepatitis C positive （HCV+） heart transplant recipients. Transplant Proc，1997，29:581-582.
[46] Sato Y，Takatsu Y，Yamada T，et al. Interferon treatment for dilated cardiomyopathy and striated myopathy associated with hepatitis c virus infection based on serial measurements of serum concentrations of cardiac troponint. Jpn Circ J，2000，64:321-324.
[47] Sato Y，Kataoka K，Matsumori A，et al. Measuring serum aminoterminal type iii procollagen peptide，7s domain of type ivcollagen， and cardiac troponint in patients with idiopathic dilated cardiomyopathy andsecondary cardiomyopathy. Heart，1997，78:505-508.
[48] Sonnenblick M，Rosin A. Cardiotoxicity of interferon:a review of 44 cases. Chest，1991，99:557-561.

Prevalence of cardiovascular diseases in patients with chronic hepatitis C

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[3]	Qiu Jun, Wang Xueqing, Zhang Bo, et al. Percutaneous choledocholithotomy for the treatment of patients with intrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2019, 22(5): 744-747.
[4]	Zhang Wei, Shi Junmei, Wang Qian. Fisk factors for occurrence of hyperbilirubinemia in neonates [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 534-536.
[5]	Li Fang, Zou Guizhou, Ye Jun, et al. Clinical features and risk factors of patients with decompensated cirrhosis and sepsis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 557-560.
[6]	Du Min, Zhou Min, Ji Zongshu. Clinical features and risk factors of liver injuries in patients with sepsis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 369-372.
[7]	Liu Wenbo, Zhang Jianye, Bao Jiwu. Analysis of risk factors for stone recurrence in patients with common bile duct stones after ERCP and EST therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 437-440.
[8]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[9]	Wu Jing, Dong Baoji, Wu Chao. Comparison of PD-1 receptor on peripheral blood follicular helper T lymphocyte surface in chronic hepatitis C patients with low and high serum viral loads [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 192-195.
[10]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[11]	Hou Chunyang, Ma Yumei, Li Fangzhi.. Clinical efficacy of peg-IFNα and ribavirin combination in treating patients with chronic hepatitis C and genotype one and six infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 53-56.
[12]	Wang Junyan, Chen Jianting, Zhang Ting, et al.. Risk factors of nosocomial infections in patients with hepatitis B liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 101-104.
[13]	Qiu Ting, Jin Yan, Lyu Yifei, et al.. Logistic regression analysis on the risk factors of portal vein thrombosis in patients with liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 916-919.
[14]	Zheng Zhenchuan, Xu Xihai.. Pathological and clinical features and factors affecting significant liver fibrosis in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 713-716.
[15]	Yan Chenli, Wang Jingjing, Wang Jun.. Severity of coronary artery lesions and risk factors in patients with nonalcoholic fatty liver disease complicated by coronary heart disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 737-740.